Detalles de la búsqueda
1.
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial.
Clin Infect Dis
; 75(6): 975-986, 2022 09 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-35079789
2.
Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, Phase 3 trial.
J Antimicrob Chemother
; 77(9): 2506-2515, 2022 08 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-35762503
3.
HIV-1-RNA and total HIV-1-DNA loads in the genital compartment in men receiving dolutegravir- versus darunavir-based combined ART (cART) regimens during primary HIV infection.
J Antimicrob Chemother
; 77(3): 735-739, 2022 02 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-35195692
4.
Assessment of intra-sample variability in HIV-1 DNA drug resistance genotyping.
J Antimicrob Chemother
; 76(8): 2143-2147, 2021 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34050668
5.
Tenofovir disoproxil fumarate and emtricitabine maintenance strategy in virologically controlled adults with low HIV-1 DNA: 48 week results from a randomized, open-label, non-inferiority trial.
J Antimicrob Chemother
; 76(6): 1564-1572, 2021 05 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33724373
6.
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study.
Clin Infect Dis
; 71(8): 1920-1929, 2020 11 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31905383
7.
Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis.
Clin Infect Dis
; 70(5): 943-946, 2020 02 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-31804669
8.
Routine drug resistance testing in proviral HIV-1 DNA: Prevalence of stop codons and hypermutation, and associated factors.
J Med Virol
; 91(9): 1684-1687, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30927451
9.
Clinical impact of tropism testing in a real-life cohort of HIV infected patients: a retrospective observational study.
BMC Infect Dis
; 19(1): 467, 2019 May 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-31126239
10.
Very slow decline of hepatitis B virus surface antigen and core related antigen in chronic hepatitis B patients successfully treated with nucleos(t)ide analogues.
J Med Virol
; 90(5): 989-993, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29315722
11.
Vaccination Against Hepatitis B Virus (HBV) in HIV-1-Infected Patients With Isolated Anti-HBV Core Antibody: The ANRS HB EP03 CISOVAC Prospective Study.
J Infect Dis
; 213(11): 1735-42, 2016 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26768256
12.
Fluctuating anaemia in treated HIV patients: could be a PICA?
Therapie
; 68(1): 49-51, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23484661
13.
Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial.
J Infect Dis
; 204(1): 124-34, 2011 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21628666
14.
Hypogonadism: a neglected comorbidity in young and middle-aged HIV-positive men on effective combination antiretroviral therapy.
AIDS
; 36(8): 1061-1071, 2022 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35113044
15.
Lopinavir/ritonavir resistance in patients infected with HIV-1: two divergent resistance pathways?
J Med Virol
; 83(10): 1677-81, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-21755502
16.
History of COVID-19 Symptoms and Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Northern France after the First Wave of the Pandemic.
Microorganisms
; 9(12)2021 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34946093
17.
Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study.
J Acquir Immune Defic Syndr
; 87(2): 794-800, 2021 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33587500
18.
Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials.
J Acquir Immune Defic Syndr
; 88(4): 393-398, 2021 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34506342
19.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Lancet HIV
; 8(11): e679-e689, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34648734
20.
Virological Outcome After Choice of Antiretroviral Regimen Guided by Proviral HIV-1 DNA Genotyping in a Real-Life Cohort of HIV-Infected Patients.
AIDS Patient Care STDS
; 34(2): 51-58, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32049556